Spruce Biosciences Inc
SPRB
Get informed when a big investor buys or sells
+ FollowMarket Cap$121.24M
Close$
$62.84
51.5% upside
Current Fair Value
51.5% upsideUndervalued by 51.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $121.24 Million |
|---|---|
| Enterprise Value | $27.69 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-50.83 |
| Beta | 3.3 |
| Outstanding Shares | 2,431,075 |
Return
| Return on Equity | -61.33% |
|---|---|
| Return on Assets | -49.93% |
| Return on Invested Capital | -51.79% |
Valuation & Multiples
| P/E Ratio | -1.08 |
|---|---|
| PEG | -0.16 |
| Price to Sales | - |
| Price to Book Ratio | 1.22 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.58 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-8.12
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-5.68
Average shareholder expectationRevenue Estimate
$50.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 82.76%▲ 28.84% |
|---|---|
| Total Invested | $108.64M▲ 124.72% |
| Investors Holding | 65▲ 33.00% |
ESG Score
No data
About Spruce Biosciences Inc
17 employeesSpruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product cand...